<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>DNA from 161 patients with various forms of <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> were investigated for mutations in exons 1 and 2 of the N-<z:mp ids='MP_0011356'>RAS</z:mp>, K-<z:mp ids='MP_0011356'>RAS</z:mp> and Ha-<z:mp ids='MP_0011356'>RAS</z:mp> gene by direct sequencing of DNA amplified in vitro by the polymerase chain reaction </plain></SENT>
<SENT sid="1" pm="."><plain>Mutations involving either codons 11, 12, or 13 of the N-<z:mp ids='MP_0011356'>RAS</z:mp> gene were identified in 18 of the 161 patients </plain></SENT>
<SENT sid="2" pm="."><plain>The relative frequencies of N-<z:mp ids='MP_0011356'>RAS</z:mp> gene mutations in these <z:e sem="disease" ids="C1521860" disease_type="Disease or Syndrome" abbrv="">hematologic disorders</z:e> was as follows: <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), 15%; <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (ALL), 14%; <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo>, 24%; and myeloid and lymphoid <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blast crisis</z:e> of <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>), 3% </plain></SENT>
<SENT sid="3" pm="."><plain>No correlation was observed between the presence of mutations and cytologic features or immunophenotype of these <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Mutations involving codons 12 or 13 were equally prevalent, with a glycine to aspartic acid substitution being the most frequently encountered change </plain></SENT>
<SENT sid="5" pm="."><plain>A single <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">T-ALL</z:e> case had a codon 11 mutation resulting in substitution of alanine with threonine </plain></SENT>
<SENT sid="6" pm="."><plain>We failed to find mutations in exons 1 and 2 of the K-<z:mp ids='MP_0011356'>RAS</z:mp> or Ha-<z:mp ids='MP_0011356'>RAS</z:mp> genes in any case except a single <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> with a mutation in codon 61 of the K-<z:mp ids='MP_0011356'>RAS</z:mp> gene </plain></SENT>
<SENT sid="7" pm="."><plain>Also, no mutations were identified in <z:hpo ids='HP_0011010'>chronic</z:hpo> phase of <z:mp ids='MP_0005481'>CML</z:mp>, <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>Ph1 positive ALL, non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e>, or <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>These results indicate that <z:mp ids='MP_0011356'>RAS</z:mp> mutations, especially those involving exon 1 of the N-<z:mp ids='MP_0011356'>RAS</z:mp> gene, are frequent only in a subset of <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> </plain></SENT>
</text></document>